MHLW Approves Lilly's Gemzar For Breast Cancer
This article was originally published in PharmAsia News
Executive Summary
The Second Committee on New Drugs at the Ministry of Health, Labor and Welfare approved Eli Lilly's Gemzar (gemcitabine) for patients with metastic breast cancer